Shares of Myokardia Inc (NASDAQ:MYOK) have earned a consensus broker rating score of 1.00 (Strong Buy) from the three analysts that cover the company, Zacks Investment Research reports. Three equities research analysts have rated the stock with a strong buy recommendation.
Brokers have set a 1 year consensus target price of $23.00 for the company and are anticipating that the company will post ($0.76) EPS for the current quarter, according to Zacks. Zacks has also assigned Myokardia an industry rank of 73 out of 265 based on the ratings given to its competitors.
In related news, major shareholder Sanofi acquired 900,000 shares of the business’s stock in a transaction on Tuesday, November 3rd. The stock was purchased at an average cost of $10.00 per share, for a total transaction of $9,000,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Mark L. Perry acquired 5,000 shares of the business’s stock in a transaction on Tuesday, November 3rd. The shares were bought at an average price of $10.00 per share, with a total value of $50,000.00. Following the completion of the transaction, the director now directly owns 25,408 shares of the company’s stock, valued at $254,080. The disclosure for this purchase can be found here.
Myokardia (NASDAQ:MYOK) opened at 14.66 on Monday. The company’s market capitalization is $396.60 million. Myokardia has a 1-year low of $8.98 and a 1-year high of $16.76. The stock has a 50 day moving average price of $12.83 and a 200-day moving average price of $12.23.
A number of equities analysts have issued reports on MYOK shares. Cowen and Company started coverage on Myokardia in a report on Monday, November 23rd. They set an “outperform” rating and a $24.00 target price for the company. Wedbush started coverage on Myokardia in a report on Monday, November 23rd. They set an “outperform” rating and a $22.00 target price for the company. Credit Suisse started coverage on Myokardia in a report on Monday, November 23rd. They set an “outperform” rating and a $18.00 target price for the company. Finally, Wells Fargo started coverage on Myokardia in a report on Thursday, December 3rd. They set an “outperform” rating for the company.
MyoKardia, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in the development of therapies for treating cardiovascular diseases. The Company focuses on developing and discovering therapies for hypertrophic cardiomyopathy (NASDAQ:MYOK) and dilated cardiomyopathy (DCM). In addition, the Company is evaluating MYK-461 and initiated a Phase I clinical program for the treatment of HCM.
For more information about research offerings from Zacks Investment Research, visit Zacks.com